BioSpace News Archive

Campaign continues to gain momentum, reaching 271 million people online.

They will be making multiple presentations at HIMSS18 on how healthcare organizations can turn on interoperability.

The powder finished dosage form is made in the U.S.A. and packaged in bottles providing 60 mL of usable volume after constitution.

In addition, Merck scientists will present data from experiments investigating the mechanisms of formation and maintenance of HIV reservoirs and the impact of HIV persistence in the gut on immune recovery during antiretroviral therapy.

Fostamatinib disodium is an oral investigational drug candidate designed to inhibit spleen tyrosine kinase, a key signaling component of the body’s immune process that leads to platelet destruction in ITP and red blood cell destruction in AIHA.

Automation technology applies AI to RTLS, EHR and other data to streamline patient flow, reduce wait times and improve throughput in hospitals.

Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease.

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its fourth quarter and full year 2017 financial results and operational progress on Thursday, March 8, 2018, after the close of the U.S. financial markets.

- Data from Phase 1 study of APD371 in healthy volunteers demonstrate safety and tolerability - Healthy volunteers did not exhibit psychotropic effects commonly seen with cannabinoids - Preclinical studies show thousand-fold selectivity for CB2 over CB1 receptors

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced an animal health research and development collaboration with AskAt Inc, including an option agreement for multiple therapeutic candidates with potential in pain, allergy and cancer.